Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Fulton Velez"'
Autor:
Felicia Forma, Ramya Pratiwadi, Fadoua El-Moustaid, Nathaniel Smith, Frances Thorndike, Fulton Velez
Publikováno v:
Current Medical Research and Opinion. 38:1727-1738
The purpose of this study was to compare the effectiveness of the only Food and Drug Administration-authorized prescription digital therapeutic (PDT) Somryst versus face-to-face cognitive behavioral therapy for insomnia (CBT-I), or FDA-approved presc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3444de7b7d9ba51cc624aadde2c2ce29
https://doi.org/10.1080/03007995.2022.2108616
https://doi.org/10.1080/03007995.2022.2108616
Autor:
Felicia Forma, Tyler Knight, Rebecca Baik, Matthew Wallace, Dan Malone, Xiaorui Xiong, Fulton Velez, Frances Thorndike, Yuri Maricich
Publikováno v:
CNS Spectrums. 28:228-229
IntroductionThis analysis examined the impact of a digital therapeutic for treating chronic insomnia (currently marketed as Somryst®, at the time called Sleep Healthy Using The internet [SHUTi]) on healthcare resource use (HCRU) by comparing patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e8b07fe9755f9955522ad0ed01604dd
https://doi.org/10.1017/s1092852923001529
https://doi.org/10.1017/s1092852923001529
Autor:
Charles Ruetsch, Sam Colman, Kathryn Anastassopoulos, Laura Kauffman, Yuri A. Maricich, Fulton Velez
Publikováno v:
ClinicoEconomics and Outcomes Research: CEOR
Fulton F Velez,1 Sam Colman,2 Laura Kauffman,2 Charles Ruetsch,3 Kathryn Anastassopoulos,2 Yuri A Maricich1 1Pear Therapeutics, Inc., Boston, MA, USA; 2Covance Market Access, Gaithersburg, MD, USA; 3Health Analytics, Columbia, MD, USACorrespondence:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c39e2426000290d7c7060a95d6270ca5
https://doi.org/10.2147/ceor.s334274
https://doi.org/10.2147/ceor.s334274
Publikováno v:
Hospital Practice. 49:348-355
Purpose To evaluate real-world prescription digital therapeutic (PDT) use and associated clinical outcomes among patients with opioid use disorder (OUD). Patients and methods A real-world observational evaluation of patients who filled either a 12- o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82d7b1cee13ecd791a9e1bedabb0dbbf
https://doi.org/10.1080/21548331.2021.1974243
https://doi.org/10.1080/21548331.2021.1974243
Publikováno v:
SLEEP. 46:A150-A150
Introduction Cognitive-behavioral therapy for insomnia (CBT-I) is the recommended first-line treatment, but sedative-hypnotic medications are often used first, despite contraindications and risk of misuse. This study assessed change in sedative/hypno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::21e71405758edebc50dbb140756b3713
https://doi.org/10.1093/sleep/zsad077.0337
https://doi.org/10.1093/sleep/zsad077.0337
Autor:
Benjamin Parcher, Dylan Mezzio, Hilary F. Luderer, Fulton Velez, Robert Gerwien, Daniel C. Malone
Publikováno v:
Postgraduate Medicine. 133:421-427
Background: The opioid epidemic continues to generate a significant mental and physical health burden on patients, and claims the life of almost 150 Americans daily. Making matters worse, an increase in relapses and/or opioid-related deaths has been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07c3c5b6d3ad22562c5517f7f57841f0
https://doi.org/10.1080/00325481.2021.1884471
https://doi.org/10.1080/00325481.2021.1884471
Publikováno v:
International Forum of Allergy & Rhinology
BACKGROUND Chronic rhinosinusitis with or without nasal polyps (CRSwNP/CRSsNP) seriously impairs health-related quality of life (HRQoL). This analysis describes the impact of the exhalation delivery system with fluticasone (EDS-FLU) on HRQoL, assesse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96ddd1e0e9cd694f531f39d345ce8b4d
http://europepmc.org/articles/PMC7818430
http://europepmc.org/articles/PMC7818430
Publikováno v:
Sleep. 45:A212-A213
Introduction Limitations on the availability of guideline-recommended cognitive behavioral therapy for insomnia (CBT-I) constrain its use and create an unmet need for innovative ways to expand access. Digital therapeutics offer a potential solution.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8305301d00fcd6603865f147a983c81d
https://doi.org/10.1093/sleep/zsac079.478
https://doi.org/10.1093/sleep/zsac079.478
Autor:
Fulton Velez, Daniel C. Malone
Publikováno v:
Journal of Market Access & Health Policy
article-version (VoR) Version of Record
Journal of Market Access & Health Policy, Vol 9, Iss 1 (2021)
article-version (VoR) Version of Record
Journal of Market Access & Health Policy, Vol 9, Iss 1 (2021)
The lack of adequate treatment for many patients with opioid use disorder (OUD) has led to high medical costs ($90B in 2020). An analysis of the cost-effectiveness (cost-utility) of reSET-O, the first and only FDA-approved prescription digital therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4244f0c7e5011f17deced6d9087cc6b
https://pubmed.ncbi.nlm.nih.gov/34434535
https://pubmed.ncbi.nlm.nih.gov/34434535
Autor:
Laura Kauffman, Sean M. Murphy, Fulton Velez, Sam Colman, Kathryn Anastassopoulos, Yuri A. Maricich
Publikováno v:
Hospital practice (1995). 49(5)
Outcomes associated with buprenorphine therapy for the treatment of opioid use disorder (OUD) are suboptimal. reSET-O is an FDA-authorized prescription digital therapeutic (PDT) delivering neurobehavioral therapy via mobile devices to patients with O
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a82c525eb63be6072a643a55e5bbecd1
https://pubmed.ncbi.nlm.nih.gov/34275401
https://pubmed.ncbi.nlm.nih.gov/34275401